Abstract:

Much substantial evidence suggests that financial toxicity has become an issue in the era of molecular and immune therapy of cancer treatment. Some independent factors related to financial toxicity including illness status， patients’ general health， age， race， income， health insurance. Financial problem can lead to lower quality of life， poor medical care， treatment nonadherence， impaired working ability and thus increase the mortality. Therefore， the interventions should be done in multiple levels and requires all parts of populaion involved. At the same time， we need more evidence-based research and statistics for guidance.

Key words:

Tumor')">"> Tumor, Financial toxicity, Immune therapy, Molecular target therapy, Side effect